Pharmaceutical Research

, Volume 15, Issue 5, pp 755–761

The Quantitative Analysis of Crystallinity Using FT-Raman Spectroscopy

  • Lynne S. Taylor
  • George Zografi


Purpose. To establish if FT-Raman Spectroscopy can be used to quantitate the degree of crystallinity in a model compound.

Methods. Mixtures containing different proportions of amorphous and crystalline indomethacin were prepared. Using the peak intensity ratio 1698 cm−1 (crystalline) to 1680 cm−1 (amorphous), a correlation curve was prepared. This correlation curve was validated by testing further samples of known composition. Partially crystalline indomethacin was prepared by milling crystalline indomethacin.

Results. A linear correlation curve was obtained across the entire range of 0−100% crystallinity. Using this method, it was possible to detect down to either 1% amorphous or crystalline content. The largest errors were found to result from inhomogeneities in the mixing of the calibration and validation samples. The spectra of the mechanically processed samples were similar to the spectra of the calibration samples, and the degree of crystallinity could be estimated in these samples.

Conclusions. FT-Raman Spectroscopy is a potentially useful method to complement existing techniques for the quantitative determination of crystallinity.

FT-Raman Spectroscopy indomethacin crystallinity quantitation 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    B. C. Hancock and G. Zografi. Characteristics and significance of the amorphous state. J. Pharm. Sci. 86:1–12 (1997).CrossRefPubMedGoogle Scholar
  2. 2.
    A. Saleki-Gerhardt, C. Ahlneck, and G. Zografi. Assessment of disorder in crystalline solids. Int. J. Pharm. 101:237–247 (1994).Google Scholar
  3. 3.
    H. P. Klug and L. E. Alexander. X-Ray diffraction procedures for polycrystalline and amorphous materials. Wiley, New York, 1974.Google Scholar
  4. 4.
    D. B. Black and E. G. Lovering. Estimation of the degree of crystallinity in digoxin by X-ray and infrared methods. J. Pharm. Pharmacol. 29:684–687 (1977).PubMedGoogle Scholar
  5. 5.
    T. Sebhatu, M. Angberg, and C. Alhneck. Assessment of the degree of disorder in crystalline solids by isothermal microcalorimetry. Int. J. Pharm. 104:135–144 (1994).Google Scholar
  6. 6.
    F. W. Langkilde, J. Sjöblom, L. Tekenbergs-Hjelte, and J. Mrak. Quantitative FT-Raman analysis of two crystal forms of a pharmaceutical compound. J. Pharm. Biomed. Anal. 15:687–696 (1997).PubMedGoogle Scholar
  7. 7.
    C. M. Deeley, R. A. Spragg, and T. L. Threlfall. A comparison of Fourier transform infrared and near-infrared Fourier transform Raman spectroscopy for quantitative measurements: an application in polymorphism. Spectrochimica Acta 47A:1217–1223 (1991).Google Scholar
  8. 8.
    A. M. Tudor, S. J. Church, P. J. Hendra, M. C. Davies, and C. D. Melia. The qualitative and quantitative analysis of chlorpropamide mixtures by near-infrared Fourier transform Raman spectroscopy. Pharm. Res. 10:1772–1776 (1993).PubMedGoogle Scholar
  9. 9.
    L. S. Taylor and G. Zografi. Spectroscopic characterization of interactions between PVP and indomethacin in amorphous molecular dispersions. Pharm. Res. 14:1691–1698 (1997).PubMedGoogle Scholar
  10. 10.
    D. E. Bugay, A. W. Newman, and P. Findlay. Quantitation of cefepime 2 HCl in cefepime 2HCl monohydrate by diffuse reflectance IR and powder X-ray diffraction techniques. J. Pharm. Biomed. Anal. 15:49–61 (1996).PubMedGoogle Scholar
  11. 11.
    M. Otsuka, T. Matsumoto, and N. Kaneniwa. Effect of environmental temperature on polymorphic solid-state transformation of indomethacin during grinding. Chem. Pharm. Bull. 34:1784–1793 (1986).PubMedGoogle Scholar
  12. 12.
    M. Yoshioka, B. C. Hancock, and G. Zografi. Crystallization of indomethacin from the amorphous state below and above its glass transition temperature. J. Pharm. Sci. 83:1700–1705 (1994).PubMedGoogle Scholar
  13. 13.
    C. G. Kontoyannis, N. C. Bouropoulos, and P. G. Koutsoukos. Use of Raman spectroscopy for the quantitative analysis of calcium oxalate hydrates: application for the analysis of urinary stones. Appl. Spectrosc. 51:64–67 (1997).Google Scholar
  14. 14.
    R. Hüttenrauch, S. Fricke, and P. Zielke. Mechanical activation of pharmaceutical systems. Pharm. Res. 2:302–306 (1985).Google Scholar
  15. 15.
    J. C. Miller and J. N. Miller. Statistics for Analytical Chemistry. Ellis Horwood, New York 1993, pp. 101–139.Google Scholar
  16. 16.
    L. E. Briggner, G. Buckton, K. Bystrom, and P. Darcy. The use of isothermal microcalorimetry in the study of changes in crystallinity induced during the processing of powders. Int. J. Pharm. 105:125–135 (1994).Google Scholar
  17. 17.
    M. V. Pellow-Jarman, P. J. Hendra, and R. J. Lehnert. The dependence of Raman signal intensity on particle size for crystal powders. Vibrational Spectroscopy 12:257–261 (1996).Google Scholar
  18. 18.
    P. A. Hailey, P. Doherty, P. Tapsell., T. Oliver, and P. K. Aldridge. Automated system for the on-line monitoring of powder blending processes using near-infrared spectroscopy Part I. System development and control. J. Pharm. Biomed. Anal. 14:551–559 (1996).PubMedGoogle Scholar
  19. 19.
    D. J. Wargo and J. K. Drennen. Near-infrared spectroscopic characterization of pharmaceutical powder blends. J. Pharm. Biomed. Anal. 14:1415–1423 (1996).PubMedGoogle Scholar
  20. 20.
    M. C. Davies, J. S. Binns, C. D. Melia, P. J. Hendra, D. Bourgeois, S. P. Church, and P. J. Stephenson. FT Raman spectroscopy of drugs in polymers. Int. J. Pharm. 66:223–232 (1990).Google Scholar
  21. 21.
    P. J. Hendra. Fourier transform-Raman spectroscopy in pharmaceutical analysis and research. American Laboratory 28:17–24 (1996).Google Scholar

Copyright information

© Plenum Publishing Corporation 1998

Authors and Affiliations

  • Lynne S. Taylor
    • 1
  • George Zografi
    • 1
  1. 1.School of PharmacyUniversity of Wisconsin-MadisonMadison

Personalised recommendations